Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston-MA, 02115, USA.
Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston-MA, 02115, USA.
Semin Immunol. 2017 Apr;30:3-11. doi: 10.1016/j.smim.2017.07.004. Epub 2017 Jul 31.
Since its first description by Wells and Osbourne in 1911, oral tolerance has intrigued researchers due to its potential for therapeutic applications. Oral tolerance can be defined as an inhibition of specific immune responsiveness to subsequent parenteral injections of proteins to which an individual or animal has been previously exposed via the oral route. Tolerance induction to commensal bacteria and dietary proteins represents the major immunological event taking place in the gut in physiological conditions. Multiple mechanisms have been proposed to explain the immune hyporesponsiveness to fed antigens: low doses of orally administered antigen are reported to favor active suppression with the generation of regulatory cells, whereas high doses would favor clonal anergy/deletion. In this review, we highlight historical aspects and the mechanisms proposed for oral tolerance induction.
自 1911 年 Wells 和 Osbourne 首次描述以来,由于其在治疗应用方面的潜力,口服耐受一直引起研究人员的兴趣。口服耐受可定义为个体或动物先前经口服途径暴露于蛋白质后,对随后的同种蛋白进行的皮内注射的特异性免疫反应受到抑制。共生菌和膳食蛋白的耐受诱导代表了生理条件下肠道中发生的主要免疫事件。已经提出了多种机制来解释对摄入抗原的免疫低反应性:据报道,口服给予的低剂量抗原有利于通过产生调节细胞进行主动抑制,而高剂量抗原则有利于克隆失能/删除。在这篇综述中,我们重点介绍了口服耐受诱导的历史方面和提出的机制。